Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - A possible influence of FcγRIIIa genetic polymorphism

British Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2008, Pages 60-68

  Ternant, David ^a   Büchler, Matthias ^b   Bénéton, Maud ^a   Alván, Gunnar ^c   Ohresser, Marc ^a   Touchard, Guy ^d   Hurault De Ligny, Bruno ^e   Toupance, Olivier ^f   Watier, Hervé ^a   Lebranchu, Yvon ^b   Paintaud, Gilles ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Antilymphocyte serum; Dose response relationship; IgG receptors; Kidney transplantation; Pharmacogenetics; Pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; CD16 ANTIGEN; CYCLOSPORIN A; DEXCHLORPHENIRAMINE; LYMPHOCYTE ANTIBODY; LYMPHOGLOBULINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CIRCULATION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HUMAN; IC 50; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, IGG; TIME FACTORS;

EID: 37249057850     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02967.x     Document Type: Article

References (29)

1. Muller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, Lange H. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997 64 : 1432 7.
2. Oertel M, Sack U, Kohlhaw K, Lehmann I, Emmrich F, Berr F, Hauss J, Schwarz R. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study. Transpl Int 2002 15 : 463 71.
3. Abouna GM, al-Abdullah IH, Kelly-Sullivan D, Kumar MS, Loose J, Phillips K, Yost S, Seirka D. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995 59 : 1564 8.
4. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998 91 : 2360 8.
5. Koene HR, Kleijer M, Algra J, von Roos D, dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R./H phenotype. Blood 1997 90 : 1109 14.
6. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997 100 : 1059 70.
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002 99 : 754 8.
8. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 21 : 3940 7.
9. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005 16 : 1675 82.
10. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005 23 : 474 81.
11. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006 11 : 11.
12. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003 277 : 185 92.
13. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994 56 : 406 19.
14. Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996 45 : 29 32.
15. Bieber CP, Griepp RB, Oyer PE, Wong J, Stinson EB. Use of rabbit antithymocyte globulin in cardiac transplantation. Relationship of serum clearance rates to clinical outcome. Transplantation 1976 22 : 478 88.
16. Guttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997 29 : 24S 26S.
17. Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, Rosenthal H, Redei I. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003 9 : 460 71.
18. Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005 11 : 609 18.
19. Schmidtke JR, Rynasiewicz J, Gifford RR Sr., Ferguson RM, Najarian JS. In vivo elimination of equine antilymphocyte globulin by renal allograft recipients. Clin Immunol Immunopathol 1980 15 : 409 14.
20. Filo RS, Book B, Pescovitz MD, Milgrom ML, Leapman SB. Association of sensitization to horse antilymphocyte/thymocyte globulin with recipient age and decreased renal allograft survival rates. Transplant Proc 1993 25 : 577 80.
21. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991 51 : 669 73.
22. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, Revillard JP. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001 71 : 460 8.
23. Michallet MC, Saltel F, Preville X, Flacher M, Revillard JP, Genestier L. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003 102 : 3719 26.
24. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004 336 : 1239 49.
25. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004 64 : 4664 9.
26. Wagner B. Immunoglobulins and immunoglobulin genes of the horse. Dev Comp Immunol 2006 30 : 155 64.
27. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 : 2635 42.
28. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004 19 : 511 9.
29. Miescher S, Spycher MO, Amstutz H, De Haas M, Kleijer M, Kalus UJ, Radtke H, Hubsch A, Andresen I, Martin RM, Bichler J. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 2004 103 : 4028 35.